EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Medial temporal lobe tau–neurodegeneration mismatch from structural imaging and plasma biomarkers

Xueying Lyu iD, Nidhi S Mundada, Christopher A Brown iD, Niyousha Sadeghpour, Emily McGrew, Long Xie, Yue Li, Anika Wuestefeld, Michael Tran Duong iD, Philip Cook, James Gee, Ilya M Nasrallah und 8 weitere

Brain · 04.11.2026 · 149 (11) · 3890-3904

DOI: 10.1093/brain/awag105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 28.04.2026. Verfasst von Xueying Lyu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: tau Proteins, Alzheimer Disease, Temporal Lobe. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, Pennsylvania Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although tau pathology is closely associated with neurodegeneration in Alzheimer’s disease, our prior work using multi-modality imaging revealed that mismatch between tau (T) and neurodegeneration (N) might reflect contributions from non-Alzheimer’s disease processes. The medial temporal lobe (MTL), an early site of Alzheimer’s disease pathology, is also a common target of co-pathologies, such as limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC), often following an anterior-to-posterior atrophy gradient. Given the susceptibility of MTL to co-pathologies, here we explored T-N mismatch specifically within MTL using plasma ptau217 and MTL morphometry for identifying vulnerabilities and resilience in cognitively impaired or unimpaired patients with Alzheimer’s disease. We parcellated the MTL into 100 spatially contiguous segments and calculated their T-N mismatch using plasma ptau217 as a measure for T and thickness as a marker of N. Based on these mismatch profiles, we clustered 447 amyloid-positive individuals from the Alzheimer’s Disease Neuroimaging Initiative cohort into data-driven T-N phenotypes. We characterized the T-N phenotypes by examining their cross-sectional and longitudinal atrophy both within the MTL and across the whole brain, in addition to cognitive trajectories. This framework was replicated in an independent cohort and, finally, translated to a real-world clinical sample of 50 patients undergoing anti-amyloid therapy. Clustering identified three T-N phenotypes with different MTL T-N mismatch profiles, atrophy patterns and cognitive outcomes, despite comparable Alzheimer’s disease severity. The ‘canonical’ group, characterized by low T-N residuals (N ∼ T), showed Alzheimer’s disease-like neurodegeneration patterns. The ‘vulnerable’ group, characterized by disproportionately greater neurodegeneration than tau (N > T), showed atrophy primarily in the anterior MTL that extended into temporal-limbic regions, in both cross-sectional and longitudinal analyses. This group also exhibited neurodegeneration that preceded estimated tau onset and experienced faster cognitive decline across multiple domains, aligning with the typical characteristics of mixed LATE-NC with Alzheimer’s disease. In contrast, the ‘resilient’ group (N < T) showed minimal atrophy and preserved cognitive function. These phenotypes were reproducible in an independent research cohort. Importantly, in a feasibility study applying the model developed from the Alzheimer’s Disease Neuroimaging Initiative to a clinical cohort of patients receiving lecanemab, we identified vulnerable individuals with LATE-like atrophy patterns. This highlights its potential utility for identifying individuals with co-pathology in clinical settings. Our findings demonstrate that T-N mismatch within MTL using MRI and plasma biomarkers can reveal Alzheimer’s disease groups with varying vulnerability/resilience, with the vulnerable group displaying structural and cognitive outcomes suggestive of LATE-NC. This approach offers a cost-effective strategy for clinical trial stratification and precision medicine for Alzheimer’s disease therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsAlzheimer DiseaseTemporal LobeHumansFemaleMaleBiomarkersAgedMagnetic Resonance ImagingAged, 80 and overAtrophy

Stichwörter der Autor:innen

Alzheimer’s diseaseLATE-NCmedial temporal lobemismatchplasma ptau217resilience

Substanzen

tau ProteinsBiomarkers

Autor:innen und Institutionen

  • Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Clinical Sciences Lund, Lund University, Lund SE-221 00, Sweden.

ORCID-Profile: Xueying Lyu, Christopher A Brown, Michael Tran Duong, Paul A Yushkevich

Förderung

  • NIA NIH HHS
  • NIH HHS
  • Pennsylvania Department of Health
  • Lund University
  • Bente Rexed Gerstedt Foundation
  • Swedish Research Council
  • Alzheimer's Association
  • Fred and Barbara Erb Family Foundation

Zitieren

APA

Lyu, X., Mundada, N. S., Brown, C. A., Sadeghpour, N., McGrew, E., Xie, L., Li, Y., Wuestefeld, A., Duong, M. T., Cook, P., Gee, J., Nasrallah, I. M., Chen-Plotkin, A. S., Shaw, L. M., Mechanic-Hamilton, D., Wisse, L. E. M., Yushkevich, P. A., Das, S. R., Wolk, D. A., & Alzheimer’s Disease Neuroimaging Initiative (2026). Medial temporal lobe tau–neurodegeneration mismatch from structural imaging and plasma biomarkers. Brain, 149(11), 3890-3904. https://doi.org/10.1093/brain/awag105

Vancouver

Lyu X, Mundada NS, Brown CA, Sadeghpour N, McGrew E, Xie L, et al. Medial temporal lobe tau–neurodegeneration mismatch from structural imaging and plasma biomarkers. Brain. 2026;149(11):3890-3904. doi:10.1093/brain/awag105

BibTeX
@article{Lyu2026,
  author = {Lyu, Xueying and Mundada, Nidhi S and Brown, Christopher A and Sadeghpour, Niyousha and McGrew, Emily and Xie, Long and Li, Yue and Wuestefeld, Anika and Duong, Michael Tran and Cook, Philip and Gee, James and Nasrallah, Ilya M and Chen-Plotkin, Alice S and Shaw, Leslie M and Mechanic-Hamilton, Dawn and Wisse, Laura E M and Yushkevich, Paul A and Das, Sandhitsu R and Wolk, David A and Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Neuroimaging Initiative},
  title = {Medial temporal lobe tau–neurodegeneration mismatch from structural imaging and plasma biomarkers},
  journal = {Brain},
  year = {2026},
  volume = {149},
  number = {11},
  pages = {3890--3904},
  doi = {10.1093/brain/awag105}
}
Kostenlos starten →